Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 16, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of shareholding changes rather than a financial performance report.
Material Changes
The filing details a change in the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan") due to a fund movement on January 12, 2006:
- Prior Holding: 18,447,919 ADRs
- New Holding: 18,372,454 ADRs
- Average Price: $51.95
Two directors, Dr. J.P. Garnier and Dr. T. Yamada, are noted as potentially interested in these shares as beneficiaries of the discretionary fund, similar to other employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a notification of a transaction under Disclosure Rule 3.1.4R(1)(b).
Investor Verification Points
- Verify the impact of the ADR reduction (75,465 shares) on the total outstanding share count.
- Confirm the specific nature of the "fund movement" that triggered the change in holdings.
- Review the full terms of the GlaxoSmithKline US Retirement Savings Plan to understand the directors' potential interest.